Eversource Energy: A Growth Story Still Developing

Eversource Energy maintains a Buy rating, underpinned by a $26.5B capital-expenditure plan, strong cash flow and an investment-grade balance sheet. The utility targets 5%-7% annual non-GAAP EPS growth, with growth expected to rebound after 2026, while its 4.5% forward dividend yield exceeds the sector median. Aquarion Water asset sales and Moody's outlook upgrade improve credit metrics and support the company’s capital-allocation plans.

Analysis

ES is transitioning from a balance-sheet repair story into a rate-base execution story. The key valuation driver is not the stated EPS algorithm but whether regulators allow timely recovery on the incremental grid-spend program without extending regulatory lag; each 100bp miss versus allowed ROE or material disallowance would pressure the post-2026 earnings inflection and likely cap multiple expansion. The recent asset monetization improves financing flexibility, but a capital program of this scale still leaves ES sensitive to Treasury yields, equity issuance, and construction-cost inflation over the next 12-24 months.

Relative to Northeast utility peers, ES offers an unusually visible path to earnings reacceleration, while its yield provides some duration protection if rates decline. The second-order beneficiary is MCO only marginally: a sustained credit-profile improvement reduces downgrade risk, but rating stabilization is already largely reflected in a high-quality utility credit narrative and is not a meaningful standalone equity catalyst. Near term, the stock likely trades with rates and regulatory headlines; the 1-3 month catalyst path is constructive regulatory updates and evidence that capex is being deployed within budget, while the 6-18 month rerating requires clean rate-case outcomes and no incremental equity need.

Consensus may be underestimating the residual execution risk embedded in the apparent post-2026 rebound. A regulated utility can spend heavily yet create limited shareholder value if recovered returns trail financing costs; the thesis is falsified by downward revisions to the 5%-7% growth framework, a negative regulatory ruling, or net debt/FFO failing to improve despite asset-sale proceeds.

Key Decisions for Investors

• Initiate a modest long ES position on rate-driven weakness rather than chase a credit-rating headline; target a 6-12 month holding period for regulatory de-risking and the earnings-growth inflection. Risk/reward is favorable only if the forward yield remains at a meaningful premium to the 10-year Treasury and management reaffirms no material incremental equity financing.
• Express relative value as long ES / short XLU in equal dollar amounts over 6-12 months: ES has company-specific balance-sheet and rate-base optionality, while the short offsets broad utility-duration exposure. Exit if ES underperforms XLU by 10% following its next earnings release while leverage guidance fails to improve.
• Maintain an event watch—not a trade—around the next major Connecticut/Massachusetts regulatory filings. Upgrade conviction only if allowed returns, revenue decoupling, and capex recovery mechanisms support the stated growth range; reduce exposure immediately on any material prudence review or cost disallowance.
• Do not use MCO as a direct expression of the ES thesis. Moody's benefit is immaterial to MCO earnings; its relevance is limited to monitoring whether further outlook improvement validates ES's funding-cost assumptions.